Liquisolid systems and aspects influencing their research and development by BARBORA VRANIKOVA & JAN GAJDZIOK
The Biopharmaceutical Classification System (BCS) is a scientific approach for clas-
sifying active pharmaceutical ingredients (APIs) based on their aqueous solubility and
gastrointestinal permeability (1, 2). Many of potentially new drugs exhibit poor water
solubility and belong to BCS class II (high permeability) or BCS class IV (low permeabil-
ity). For poorly soluble and highly permeable drugs (BCS class II), the solubility and dis-
solution behaviour of the drug are the most important parameters for bioavailability (3).
Due to their low bioavailability, poorly water-soluble drugs cause many difficulties
in the development of pharmaceutical dosage forms for oral delivery (4, 5). Different
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dosage forms with sufficient bioavailability. Preparation
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compressible, dry powder through its absorption into
suitable excipients – porous carriers (aluminometasilica-
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techniques have been published in the scientific literature to enhance the dissolution
profile and also the absorption efficiency and bioavailability of water-insoluble and/or
liquid lipophilic drugs. Reduction of the particle size via micronisation or nanonisation
leading to increased surface area (6); use of surfactants (7); lyophilisation (8); use of
co-solvents (9); self-emulsification and self-microemulsification (10, 11); inclusion of
APIs into cyclodextrins (12); use of pro-drugs and drug derivatisation (13); formation of
solid solutions or amorphous solids (14); microencapsulation (15) and inclusion of drug
solutions or liquid drugs into soft gelatine capsules or sealed hard shell capsules (16) are
some of the methods used to enhance dissolution characteristics of water-insoluble or
poorly soluble drugs (Fig. 1). The most promising and innovative technique for promot-
ing dissolution and in vivo bioavailability of poorly soluble drugs is the formulation of
liquisolid systems (LSS) (5, 17, 18).
From the historical point of view, liquisolid systems evolved from »powdered solu-
tions«, which are based on preparation of a true solution of the drug in a high-boiling
point, water-miscible solvent, which was incorporated into the structure of an inert car-
rier with a large surface (colloidal silica) (19). However, such preparations have been in-
vestigated for their dissolution profiles in a powder-dispersion form because they were
not suitable for compression into tablets. To increase the compressibility of the systems,
compression enhancers such as microcrystalline cellulose were added to powder solu-
tion formulations. However, properties of the products were never adapted to industrial
requirements (20).
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Fig. 1. Various techniques that can be used to enhance drug solubility (19).
Technological improvement of preparing powdered solutions were the liquisolid
systems, which essentially refer to formulations formed by conversion of liquid drugs or
drugs in liquid state (solutions, suspensions or emulsions) into dry, non-adherent, free-
-flowing and compressible powder mixtures by blending a liquid dispersion with spe-
cific carriers and coating materials (19).
The common basis of liquisolid systems are non-volatile solvents (or drugs alone)
used to prepare a drug solution, suspension or emulsion, which do not evaporate during
the preparation process and thus the drug is carried within the liquid system, which in
turn is dispersed throughout the final solid product (20). Unlike solid self-emulsifying
systems, hydrophilic solvents are used to obtain the drug in liquid solution during the
preparation of liquisolid systems. Moreover, the drug solution does not form an emul-
sion (microemulsion) after agitation in the gastrointestinal tract.
ADVANTAGES, LIMITATIONS AND APPLICATION OF LIQUISOLID SYSTEMS
Liquisolid systems have many advantages (17, 19, 21–24):
– Increased bioavailability and enhanced in vitro and in vivo drug release of an orally
administered water-insoluble drug, achieved when the drug is in the liquid form.
– A number of water-insoluble solid and liquid drugs can be formulated into liqui-
solid systems.
– LSS can be used for controlled drug delivery.
– Liquisolid systems minimize pH influence on the dissolution rate of poorly solu-
ble drugs.
– The final processing of liquisolid systems could be similar to conventional solid
dosage forms (tablets, capsules).
– Low production costs.
Limitations of LSS include the requirement of high solubility of the drug in non-vo-
latile liquid vehicles if drug solutions are used (17). The main limitation of LSS is the
problematic formulation of a high dose of poorly water soluble drugs (e.g., carbamaze-
pine, flutamide). These drugs require a large amount of liquid vehicle and also carrier
and coating material to prepare dry powder with suitable flowability and compressibil-
ity. This could increase the mass of each tablet over the limit for easy application (21, 25).
Nevertheless, Javadzadeh et al. (26) have proven that it is possible to load a large
amount of drug into a liquisolid system using additives (such as polyvinylpyrrolidone,
hydroxypropyl methylcellulose and polyethylene glycol 35 000), which can be added to
the drug in liquid state to reduce the amount of carrier and coating material. Singh et al.
(27) have shown that higher viscosity of the additives leads to smaller amounts of car-
rier and coating material needed to produce flowable powder. The use of modern carri-
ers and coating materials with a large specific surface area and high absorption capacity
(e.g., Neusilin®) is another way of incorporation of higher doses of water insoluble drugs
into liquisolid systems (28).
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Application of liquisolid systems (3, 17, 22):
– Dosage forms with enhanced release rates and improved bioavailability.
– Sustained release of water-soluble drugs (propranolol hydrochloride) can be at-
tained.
– Liquisolid technique can be successfully used in formulation of orodispersible
tablets.
Several liquisolid formulations, which were studied in vivo, have already been de-
scribed in literature. For example, El-Houssieny et al. (29) investigated the effect of liqui-
solid compacts containing repaglinide on glucose tolerance in rabbits. They proved that
the bioavailability of repaglinide was improved significantly when it was administered
orally in the form of liquisolid compacts compared to commercially available tablets.
Khaled et al. (30) evaluated in vivo the behaviour of liquisolid tablets with hydro-
chlorothiazide in beagle dogs. Liquisolid tablets showed higher values of AUCt, AUCµ,
Cmax and F parameters than commercial hydrochlorothiazide tablets. The mean values of
absolute bioavailability of hydrochlorothiazide from liquisolid tablets were increased by
~15 % in comparison with commercially available tablets.
During in vivo evaluation of carbamazepine liquisolid tablets, it was observed by
Chen et al. (31) that absolute bioavailability of carbamazepine was increased by 82 % in
comparison with commercially available tablets.
Evaluation of liquisolid tablets containing famotidine showed a higher dissolution
rate than the conventional, directly compressed tablets. Liquisolid formulation released
78 % of famotidine during the first 10 min, which is 39 % more than the release from di-
rectly compressed tablets (32).
FORMULATION OF LIQUISOLID SYSTEMS
Preparation of liquisolid systems is based on the principles of conversion of the drug
in the liquid state into a free flowing, readily compressible and apparently dry powder by
simple physical blending with selected excipients, excipients – carriers and coating mate-
rials. Liquid drug could be also sprayed into the carrier material in fluid-bed equipment
for homogenous distribution of the active substance. Liquid drug is incorporated into the
porous structure of a carrier material due to adsorption and absorption (17, 33, 34).
Excipients for liquisolid systems
Non-volatile solvents. – Various non-volatile, high-boiling point, preferably water
miscible and not highly viscous solvents are used for the formulation of liquisolid sys-
tems. It was proven in several studies that the solvent had a significant effect on drug re-
lease from liquisolid systems (35, 36). For enhanced drug release from liquisolid prepa-
rations, a liquid vehicle in which the active ingredient is most soluble is usually selected.
In the case of preparing liquisolid systems with modified release, solvents with a low ca-
pability to solubilize the drug are used.
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Propylene glycol (PG) is commonly used in the pharmaceutical industry as a stabi-
lizer for vitamins, humectant and co-solvent in ointments for medicinal applications
(37). The main function of propylene glycol is to solubilize and provide homogeneous
dispergation of the active ingredient in the formulation (38).
In their study, Gubbi and Jarag (39) found out that liquisolid compacts with brom-
hexine hydrochloride prepared using propylene glycol showed a higher dissolution rate
than bromhexine hydrochloride with PEG 400. The slower release of bromhexine hydro-
chloride from PEG 400 liquisolid compacts can be attributed to lower solubility of brom-
hexine hydrochloride in polyethylene glycol 400.
Liquid polyethylene glycols (PEG 200-600) are widely used as solvents and solubi-
lizing agents for active substances and excipients in liquid and semi-solid preparations
(40). Aqueous polyethylene glycol mixtures can also be used as suspending agents or as
thickeners. When used in conjunction with emulsifiers, polyethylene glycols can act as
emulsion stabilizers (41).
Mahajan et al. (34) investigated the effect of the type of non-volatile solvent on the
dissolution profile of glipizide from liquisolid tablets. Propylene glycol, PEG 200 and
PEG 400 were used to prepare liquisolid formulations in that study. It was observed that
all three liquid vehicles were able to increase the dissolution rate of glipizide from liqui-
solid tablets in comparison with their commercial counterparts. Liquisolid tablets con-
taining PEG 400 as liquid vehicle showed higher dissolution rates compared to liqui-
solid tablets containing PG and PEG 200 as liquid vehicles (34).
Polyoxyethylene sorbitan fatty acid esters (Polysorbate, Tween) are widely used in
pharmaceutical and cosmetic industry as emulsifiers, dispersants or stabilizers because
of their effectiveness at low concentrations and relatively low toxicity (41–43). In addi-
tion, polysorbates are compatible with the majority of active ingredients (44). The most
commonly used polysorbate in liquisolid systems is Polysorbate 80.
Polysorbate 80 was successfully used to dissolve the drug in several liquisolid sys-
tems containing carbamazepine (26, 45), indomethacin (46, 47), piroxicam (48), propra-
nolol hydrochloride (35), etc.
Other solvents that can be used in formulation of liquisolid systems include glyc-
erol, N,N-dimethylacetamide, Synperonic® PE/L 81 (polyoxyethylene-polyoxypropyle-
ne block copolymer), Caprol® PGE-860 ((9Z)-9-octadecenoate), Labrasol® (caprylocapro-
yl macrogol-8 glycerides), Transcutol® HP (highly purified diethylene glycol monoethyl
ether), Solutol® HS-15 (macrogol 15 hydroxystearate) and Cremophor® EL (macrogol
glycerol ricinoleate), which was used in studies (49) partially due to its known inhibition
effect on P-glycoprotein. This P-glycoprotein decreases the drug intestinal absorption by
efflux transportation and hence reduces its plasma concentration (18, 49–52). Also Kolli-
coat® SR 30D (polyvinyl acetate stabilized with polyvinylpyrrolidone and sodium lauryl
sulphate) can be used as a liquid vehicle in liquisolid systems for controlled drug release
(52, 53).
Carrier materials. – In the LSS preparation technique, carrier materials play the main
role in obtaining the dry form of powder from the drug in liquid state. Each carrier has
its unique properties, but each should be a porous material possessing sufficient absorp-
tion capacity for liquids (21). It was observed that the specific surface area (SSA) (Table
I) of the carrier is an important factor in the formulation of liquisolid systems (23). Car-
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rier selection depends on its liquid binding capacity, flowability of powders and com-
pressibility (19). Based on their chemical structure, carriers can be classified into four
categories (Table I).
Microcrystalline cellulose (MCC, Avicel®, Ceolus®, Vivapur®, Emcocel®) is the most
commonly used carrier in liquisolid formulations based on its long-term application in
the pharmaceutical industry, its stability and availability. It was used to formulate LSS
containing aceclofenac (57), diazepam (58), furosemide (50), etc. (Table II).
It was observed in previous studies that carriers other than MCC (such as lactose,
starch or sorbitol) were required in larger amounts for conversion of liquid preparations
to the dry, non-adherent, free-flowing powder form. This was attributed to the larger
specific surface area of MCC (Table I) (23).
Magnesium aluminometasilicates (Neusilin®, Pharmsorb®, Veegum®) are available
in various grades (e.g., 11 grades of Neusilin®) and two different pH options (alkaline
pH 8.5–10.0 and neutral pH 6.5–8.0), which make them versatile excipients for a wide
variety of applications. The most prominent magnesium aluminometasilicate Neusilin®
can be used in direct compression and also in wet granulation (59). Neusilin® US2 is pre-
pared by spray drying and thus provides an extremely large specific surface area, high
porosity and good flow and tableting properties. The high porosity and large SSA of
Neusilin® cause its high oil and water adsorption capacity (Fig. 2) (60, 61).
In liquisolid system preparation, Neusilin® can be used as a carrier or also as a coat-
ing material (see below). For example, Neusilin® S1 was used as a material absorbing ex-
cess liquid in the LSS tablets of cyclosporine A. Compared to conventional cyclosporine
tablets, the drug release from the liquisolid tablets exhibits a significant improvement (63).
Anhydrous dibasic calcium phosphate (Fujicalin®, Emcompress® Anhydrous). Fuji-
calin® is a free-flowing spherically agglomerated anhydrous dibasic calcium phosphate for
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Table I. Classification of carrier material into four categories and their SSA (28, 54–56)




















a Carrier material for LSS with controlled drug delivery
direct compression (64). It was observed that Fujicalin® had higher liquid adsorption ca-
pacity in comparison with directly compressible dicalcium phosphate dihydrate (65, 66).
Therefore, Fujicalin® can be used as a carrier material in liquisolid systems, as pro-
ved by Hentzschel et al. (28). In their study, Fujicalin® was used to prepare a liquisolid
system containing Tocopherol acetate as a model drug (28).
Based on their large SSA, several other excipients can be used as potential carriers
in a liquisolid formulation, such as kaolin (Lion®, Sim® 90), diosmectite and magnesium
carbonate.
Ordered mesoporous silicates (OMS) (SBA-15, MCM-41, TUD-1) could also have a
high potential in this field. They were originally developed for controlled drug release for-
mulations (67–69) and their capability to enhance the release of poorly soluble drugs was
discovered later (56, 70, 71). In recent studies, it was observed (72, 73) that drugs lose
crystallinity when deposited on the surface of mesoporous silicates, which enhances their
dissolution rate. In comparison with non-porous materials, deposited molecules are not
only absorbed onto the mesoporous silica surface but are also confined to pores (56).
Because of their high specific surface area (up to 1500 m2 g–1), OMS could be used
as a carrier material in liquisolid systems. Chen et al. (31) successfully used an ordered
mesoporous carrier as coating material to formulate liquisolid systems containing car-
bamazepine as a model drug, PEG 400 as a non-volatile solvent and MCC or starch 1500
as carrier materials. The significant improvement of drug loading and dissolution rate
demonstrated that those formulations could provide enhanced dissolution of poorly wa-
ter-soluble drugs (31, 74).
Coating materials. – Coating material should be a material possessing fine (0.01–5 µm
in diameter) and highly absorptive particles, which contribute to covering the wet car-
rier particles and displaying a dry powder by adsorbing excess liquid to ensure good
flowability of the created blend (20, 21). In liquisolid system formulations, this role is
played by materials with a large specific surface area and absorption capacity, which
cannot be used as carriers due to their poor flowing or compressing properties.
Nowadays, the most commonly used coating material in liquisolid formulations is
colloidal silicon dioxide (Aerosil®, Cab-O-Sil® M5). It was successfully used with ator-
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Fig. 2. Oil adsorption capacity of some grades of Neusilin® in comparison with MCC and colloidal
silica (62).
vastatin (75), naproxen (18), famotidine (32), rofecoxib (76), etc. (Table II). Amorphous
silica gel (Syloid®, Sylysia®), granulated silicon dioxide (Aeroperl®), silica aerogel, mag-
nesium alumino metasilicates (Neusilin®), calcium silicate (Florite®) and ordered meso-
porous silicates can be also used to prepare liquisolid system with suitable flowability
and compressibility (28, 29, 31, 77–79).
Pre-formulation studies
Pre-formulation studies are necessary to achieve a powder mixture with acceptable
powder flow and liquisolid formulations that satisfy all requirements generally imposed
on tablets, capsules or granules. These studies are closely related to selection of the best
non-volatile solvent to solubilize drugs and to calculate the appropriate amount of pow-
der excipients – carrier and coating material (76).
Solubility studies are carried out by preparing a saturated solution of the drug by
adding an excess of drug into non-volatile solvents and let it stay to achieve the equilib-
rium state (e.g., by shaking, stirring). After this step, the amount of drug dissolved in a
specific solvent is evaluated analytically (20, 22). Solvents with greater ability to solubilize
the drug are selected for the formulation of liquisolid systems for enhanced release (23).
Determination of the angle of slide (q) is used to evaluate the flow property of powder
excipients (18). Spireas et al. (80) claimed that the angle of slide is the preferred method
to determine the flowability of powders with particles smaller than 150 µm. The requi-
red amount of carrier is weighed and placed on one end of a metal plate with a polished
surface. This end is gradually raised until the plate makes an angle with the horizontal
surface at which powder is about to slide. This angle is known as the angle of slide. The
angle of slide of 33° is regarded as optimal flow behaviour for the subsequent processing
of liquisolid system admixtures (compressing into tablets, filling into capsules) (22, 23).
Determination of the flowable liquid retention potential (F-value). – The term flowable
liquid retention potential of a powder material describes its ability to retain a specific
amount of liquid while maintaining good flow properties. The F-value (FCA – F-value
of carrier, FCO – F-value of coating material) is defined as the maximum mass of a liquid
(mmax) that can be retained per unit mass of the powder material (Q – mass of carrier, q –
mass of coating material) in order to produce an acceptably flowing liquid/powder mix-
ture (Eq. 1) (21). The liquid retention potential is mainly dependent on the absorption
process (81).







Powder excipients are mixed with varying amounts of a non-volatile solvent and
the angle of slide of these liquid-powder admixtures is determined. The liquid/solid
mass ratio (m/m) of admixtures with the angle of slide corresponding to 33° is taken as
the F-value of the excipient (20, 23, 82, 83).
Calculation of the liquid load factor (Lf). – Lf is defined as the ratio of the mass of drug
in the liquid state (m) to the mass of carrier material (Q). It is determined by dissolving
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or dispersing the drug in different concentrations in a non-volatile solvent (84). Such a
drug in the liquid state is added to the carrier material and blended. Using Eq. 2, drug
loading factors are determined and used to calculate the amounts of carrier and coating





The powder excipients ratios (R) and liquid load factors (Lf) of the formulations are








Evaluation of liquisolid tablets containing rofecoxib showed that the liquid load fac-
tor was inversely proportional to the hardness of the tablets, i.e., when Lf increased, the
hardness of the tablets decreased. This can be explained by increasing Lf of the formula,
connected with higher amount of poorly compressible coating material used during ma-
nufacture, which led to lower hardness of tablets (76). The effect of the liquid load factor
on tablet hardness was also proved by evaluating liquisolid tablets containing griseo-
fulvin as a model drug. The formulation with a lower liquid load factor showed higher
hardness, which may be caused by the high concentration of Avicel® PH 102 (carrier)
leading to plastic deformation of the powder admixture and formation of more hydro-
gen bonds between its molecules (53).
Liquisolid compressibility test (LSC) is used to the compressible liquid retention po-
tential (y-value) and to characterize the compaction behaviour of powder excipients (85).
The y-value is the maximum mass of the liquid that can be retained per unit mass of the
powder material to produce an acceptably compressible liquisolid admixture. In fact, this
is the mass of the liquid that can afford tablets of satisfactory mechanical strength without
presenting any »liquid squeezing out« phenomena during compression (23).
Calculation of the required amount of carrier and coating material. – To calculate the re-
quired mass of excipients, Eq. 3 is used first, where FCA and FCO are constants; there-
fore, according to the ratio of the carrier/coating materials (R) (Eq. 4), Lf could be calcu-
lated from the linear relationship of Lf versus 1/R. Next, depending on the used liquid
vehicle concentration, different masses of the liquid drug (m) should be used. Then, ap-
propriate quantities of carrier (Q) and coating (q) powder materials required to trans-
form a given amount of drug in the liquid state (m) into an acceptably flowing and com-





Powder flow (flow property) is important in the formulation and industrial produc-
tion of solid dosage forms in order to get a uniform dose as well as reproducible filling
of a tablet press or capsules. The angle of repose, compressibility index or Hausner ratio,
flow rate through the orifice, shear cell and the related tapped and bulk density have to
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be executed according to the official pharmacopeia and are the main parameters of pow-
der flow (84).
Pre-compression studies of liquisolid systems containing irbesartan showed that
there was a relationship between the powder excipient ratios (R) and the angle of repose
of the liquisolid powder in the formulation having the same Lf. The powder excipients
ratio is directly proportional to the angle of repose of liquisolid powders, i.e., when the
excipient ratio increased, the angle of repose increased too, because of poorer flowing
properties of powdered blends caused by a lower content of coating material (86).
Differential scanning calorimetry (DSC) is performed in order to assess the thermal
behaviours (melting point, glass transition temperature, change of crystalline structure)
of the drug, excipients used in the formulation, as well as the liquisolid system prepared
(20). Samples (pure drug, excipients used in the liquisolid system and liquisolid formu-
lation) are sealed in aluminium pans and evaluated at a constant heating rate in the
scanning temperature range according to the drug used (87).
DSC is also used to determine any possible interaction between the drug and excipi-
ents (or between excipients), detectable by shifting of the characteristic peak, used in the
formulation. It is very important to establish the existence of any incompatibilities dur-
ing the pre-compression stage to ensure the success of subsequent stability studies. The
drug has a characteristic peak and the absence of this peak in the DSC thermogram indi-
cates that the drug is in the form of solution in the liquisolid formulation and hence it is
molecularly dispersed within the system (21, 22, 84). DSC is carried out during pre-com-
pression studies of LSS in order to ensure suitability of the selected excipients (88).
In some cases, also X-ray diffraction (XRD) studies and scanning electron micros-
copy (SEM) are recommended during the pre-compression studies of LSS to control the
crystallinity of the drug. Disappearance of characteristic peaks or crystals of the drug
generally indicates that the drug is converted into the amorphous form or is solubilized
in the liquisolid formulation (22, 84).
Preparation of liquisolid systems
The drug is dissolved or dispersed in the required amount of a non-volatile solvent
and the resulting blend is incorporated into calculated amounts of carrier and coating
materials. Mixing process is carried out in three steps. During the first step, the system is
blended at an approximate mixing rate in order to homogenously distribute the drug in
the liquid state throughout the powder. In the second step, the liquid/powder admix-
ture is evenly spread as a uniform layer and left standing to allow drug dispersion to be
absorbed in the interior of powder particles. In the third step, the powder is blended
with common excipients needed to prepare the final dosage form (tablets, capsules) (20,
22, 23). For a homogeneous distribution of API, the drug could be applied on the parti-
cles of the carrier also by spraying in a fluid-bed equipment.
Evaluation of liquisolid systems
Liquisolid systems are evaluated in the same way as conventional tablets, granules
and capsules by carrying out tests for mass variation, uniformity of dosage units, unifor-
mity of content, hardness, friability, disintegration and dissolution, all of which are de-
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scribed in official pharmacopoeias. Measured values should fall within the official limits
prescribed by pharmacopoeias (89).
Contact angle measurement. – The specific method used for evaluation of physicoche-
mical properties of LSS is measuring of the contact angle. A drop of a liquid, preferably
not dissolving or poorly dissolving the sample is placed on the surface of the tablet (20).
The naturally formed angle between a liquid and a solid is defined as contact angle (89).
This measurement is performed to evaluate the wettability of prepared liquisolid tablets
with dissolution media.
LIQUISOLID SYSTEMS FOR ENHANCED DRUG RELEASE
Many drugs of BCS class II (low solubility, high permeability), possibly of class IV
(low solubility, low permeability) have been formulated as liquisolid systems to ensure
enhanced drug release. To formulate these drug delivery systems, different liquid vehi-
cles, carriers and coating materials were used, as shown in Table II.
Mechanism of enhanced drug release from liquisolid systems
Several possibilities of enhanced drug release have been described in the literature
(90, 91). The main suggested mechanisms include: an increased surface area of the drug
available for release, increased aqueous solubility of the drug and/or improved wetta-
bility of drug particles (17, 79, 92). In addition to these mechanisms, the drug in LSS is
presented in dissolved state, which allows elimination of the most limiting step during
drug absorption in the gastrointestinal tract.
Increased drug surface area. – While the drug within the liquisolid system is comple-
tely dissolved in the liquid vehicle, it is still located on the whole surface of carrier mate-
rial in the solubilized, molecularly dispersed state. Therefore, the surface area of the
drug available for release is much larger than that of drug particles within directly com-
pressed tablets (17, 32, 92).
Improved wetting properties. – Wettability of the compacts by dissolution media is one
of the proposed mechanisms for explaining the enhanced dissolution rate from liquisolid
systems. The non-volatile solvent present in the liquisolid system facilitates wetting of
drug particles by decreasing the interfacial tension between dissolution medium and
tablet surface (21). Improved wettability of these systems has been demonstrated by
measurements of contact angles and water rising times (21, 92).
Yadav V. B. and Yadav A. V. (47) claimed that liquisolid granules containing indo-
methacin showed significantly shorter rising time of water in comparison with raw in-
domethacin and granules prepared by the compression technique. This can be mainly at-
tributed to the fact that this poorly water-soluble drug is already in solution absorbed on
powder particles of the carrier of the liquisolid formulation (47).
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LIQUISOLID SYSTEMS FOR MODIFIED DRUG RELEASE
Development of modified release oral dosage forms is beneficial for optimal ther-
apy in terms of efficacy, safety and patient compliance. It is suggested that liquisolid sys-
tems have the potential to be optimized for decrease of the drug dissolution rate and
thereby production of prolonged release preparations (matrix tablets, film-coated dos-
age forms, microparticles, etc.) (20, 92).
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Table II. List of several investigated liquisolid systems for enhanced drug release



































Loratadine (24) propylene glycol MCC Aerosil® 200




Repaglinide (29) polysorbate 80 MCC calciumsilicate
Spironolactone (52)
Synperonic®PE/L61
+ Solutol® HS-15 MCC Cab-O-Sil® M-5
Kollicoat® SR 30 D
Valsartan (94) propylene glycol MCC Aerosil® 200
The advantages of liquisolid systems to be used in prolonged release systems in-
clude simplicity, low cost and suitability for industrial production (92). However, only a
few drugs (propranolol HCl (35), theophylline (36), griseofulvin (53) and tramadol HCl
(33) have been formulated as liquisolid systems with prolonged drug release.
Liquisolid formulations with prolonged drug release may contain hydrophobic car-
riers such as Eudragit®RL or RS instead of hydrophilic carriers. Hydrophobic carriers
could lead to poor wetting properties of liquisolid systems, resulting in inadequate ac-
cess of hydrophilic dissolution media into the structure of the liquisolid compact and
thus prolonged drug release (95). Javadzadeh et al. (35) have proved that a liquid vehicle
may affect drug release. They provide evidence that polysorbate 80 plays an important
role in sustaining the release of propranolol hydrochloride from liquisolid matrix sys-
tems containing Eudragit®RL or RS as carrier material. It was shown that the liquid ve-
hicle polysorbate may act as a plasticizer and thus decrease the glass transition tempera-
ture (Tg) of the used polymer (Eudragit® RS). Plasticizers affect the intermolecular bon-
ding between polymer chains, thereby increasing their flexibility. At temperature above
Tg, a better coalescence of polymer particles occurs, and a fine network and matrix with
low porosity forms. This results in decreased entrance of dissolution media into the
compact structure. Therefore, reduction of Tg of the polymer might be the reason for re-
lease prolongation of liquisolid tablets (35).
Another way to sustain the release from liquisolid systems is combination of hydro-
philic carriers with the release modifying agent (e.g. hydroxypropyl methylcellulose)
(53, 92). Gonjari et al. (33) proved that addition of HPMC to hydrophilic carrier (Avicel
PH 102) prolonged tramadol hydrochloride release from liquisolid tablets. It was found
that liquisolid compacts show a higher prolongation effect compared to conventional
formulations.
CONCLUSIONS
Liquisolid systems essentially refer to formulations formed by conversion of the
drug in liquid state into dry, non-adherent, free flowing and compressible powder by
sorbing the liquid dispersion system to the carrier and coating material. Liquisolid sys-
tems show significantly improved bioavailability of drugs due to increased solubility
and dissolution rate of poorly water-soluble substances. The liquisolid technique can be
also used to design dosage forms with modified release by using hydrophobic carriers
instead of hydrophilic carriers. However, the technology of liquisolid systems is in the
early stages of its development. It is envisaged that liquisolid systems could play an im-
portant role in modern solid dosage forms owing to their advantages (e.g., low produc-
tion costs, final processing similar to conventional tablets or hard capsules, and unpro-
blematic industrial production).
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